International Union of Pharmacology.

XXVII. Classification of cannabinoid receptors

A C Howlett, F Barth, T I Bonner, G Cabral, P Casellas, W A Devane, C C Felder, M Herkenham, K Mackie, B R Martin, R Mechoulam, R G Pertwee

Research output: Contribution to journalLiterature review

1924 Citations (Scopus)

Abstract

Two types of cannabinoid receptor have been discovered so far, CB1 (2.1:CBD:1:CB1:), cloned in 1990, and CB2 (2.1:CBD:2:CB2:), cloned in 1993. Distinction between these receptors is based on differences in their predicted amino acid sequence, signaling mechanisms, tissue distribution, and sensitivity to certain potent agonists and antagonists that show marked selectivity for one or the other receptor type. Cannabinoid receptors CB1 and CB2 exhibit 48% amino acid sequence identity. Both receptor types are coupled through G proteins to adenylyl cyclase and mitogen-activated protein kinase. CB1 receptors are also coupled through G proteins to several types of calcium and potassium channels. These receptors exist primarily on central and peripheral neurons, one of their functions being to inhibit neurotransmitter release. Indeed, endogenous CB1 agonists probably serve as retrograde synaptic messengers. CB2 receptors are present mainly on immune cells. Such cells also express CB1 receptors, albeit to a lesser extent, with both receptor types exerting a broad spectrum of immune effects that includes modulation of cytokine release. Of several endogenous agonists for cannabinoid receptors identified thus far, the most notable are arachidonoylethanolamide, 2-arachidonoylglycerol, and 2-arachidonylglyceryl ether. It is unclear whether these eicosanoid molecules are the only, or primary, endogenous agonists. Hence, we consider it premature to rename cannabinoid receptors after an endogenous agonist as is recommended by the International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. Although pharmacological evidence for the existence of additional types of cannabinoid receptor is emerging, other kinds of supporting evidence are still lacking.

Original languageEnglish
Pages (from-to)161-202
Number of pages42
JournalPharmacological Reviews
Volume54
Issue number2
DOIs
Publication statusPublished - 2002

Keywords

  • fatty-acid amide
  • activated protein-kinase
  • central-nervous-system
  • hippocampal acetylcholine-release
  • long-term potentiation
  • Nigra Pars Reticulata
  • nitric-oxide release
  • excitatory synaptic-transmission
  • mediated signal-transduction
  • rat cerebellar membranes

Cite this

Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., ... Pertwee, R. G. (2002). International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacological Reviews, 54(2), 161-202. https://doi.org/10.1124/pr.54.2.161

International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. / Howlett, A C ; Barth, F ; Bonner, T I ; Cabral, G ; Casellas, P ; Devane, W A ; Felder, C C ; Herkenham, M ; Mackie, K ; Martin, B R ; Mechoulam, R ; Pertwee, R G .

In: Pharmacological Reviews, Vol. 54, No. 2, 2002, p. 161-202.

Research output: Contribution to journalLiterature review

Howlett, AC, Barth, F, Bonner, TI, Cabral, G, Casellas, P, Devane, WA, Felder, CC, Herkenham, M, Mackie, K, Martin, BR, Mechoulam, R & Pertwee, RG 2002, 'International Union of Pharmacology. XXVII. Classification of cannabinoid receptors', Pharmacological Reviews, vol. 54, no. 2, pp. 161-202. https://doi.org/10.1124/pr.54.2.161
Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacological Reviews. 2002;54(2):161-202. https://doi.org/10.1124/pr.54.2.161
Howlett, A C ; Barth, F ; Bonner, T I ; Cabral, G ; Casellas, P ; Devane, W A ; Felder, C C ; Herkenham, M ; Mackie, K ; Martin, B R ; Mechoulam, R ; Pertwee, R G . / International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. In: Pharmacological Reviews. 2002 ; Vol. 54, No. 2. pp. 161-202.
@article{87a53db59640424ba8ce56e4cd58fafa,
title = "International Union of Pharmacology.: XXVII. Classification of cannabinoid receptors",
abstract = "Two types of cannabinoid receptor have been discovered so far, CB1 (2.1:CBD:1:CB1:), cloned in 1990, and CB2 (2.1:CBD:2:CB2:), cloned in 1993. Distinction between these receptors is based on differences in their predicted amino acid sequence, signaling mechanisms, tissue distribution, and sensitivity to certain potent agonists and antagonists that show marked selectivity for one or the other receptor type. Cannabinoid receptors CB1 and CB2 exhibit 48{\%} amino acid sequence identity. Both receptor types are coupled through G proteins to adenylyl cyclase and mitogen-activated protein kinase. CB1 receptors are also coupled through G proteins to several types of calcium and potassium channels. These receptors exist primarily on central and peripheral neurons, one of their functions being to inhibit neurotransmitter release. Indeed, endogenous CB1 agonists probably serve as retrograde synaptic messengers. CB2 receptors are present mainly on immune cells. Such cells also express CB1 receptors, albeit to a lesser extent, with both receptor types exerting a broad spectrum of immune effects that includes modulation of cytokine release. Of several endogenous agonists for cannabinoid receptors identified thus far, the most notable are arachidonoylethanolamide, 2-arachidonoylglycerol, and 2-arachidonylglyceryl ether. It is unclear whether these eicosanoid molecules are the only, or primary, endogenous agonists. Hence, we consider it premature to rename cannabinoid receptors after an endogenous agonist as is recommended by the International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. Although pharmacological evidence for the existence of additional types of cannabinoid receptor is emerging, other kinds of supporting evidence are still lacking.",
keywords = "fatty-acid amide, activated protein-kinase, central-nervous-system, hippocampal acetylcholine-release, long-term potentiation, Nigra Pars Reticulata, nitric-oxide release, excitatory synaptic-transmission, mediated signal-transduction, rat cerebellar membranes",
author = "Howlett, {A C} and F Barth and Bonner, {T I} and G Cabral and P Casellas and Devane, {W A} and Felder, {C C} and M Herkenham and K Mackie and Martin, {B R} and R Mechoulam and Pertwee, {R G}",
year = "2002",
doi = "10.1124/pr.54.2.161",
language = "English",
volume = "54",
pages = "161--202",
journal = "Pharmacological Reviews",
issn = "0031-6997",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "2",

}

TY - JOUR

T1 - International Union of Pharmacology.

T2 - XXVII. Classification of cannabinoid receptors

AU - Howlett, A C

AU - Barth, F

AU - Bonner, T I

AU - Cabral, G

AU - Casellas, P

AU - Devane, W A

AU - Felder, C C

AU - Herkenham, M

AU - Mackie, K

AU - Martin, B R

AU - Mechoulam, R

AU - Pertwee, R G

PY - 2002

Y1 - 2002

N2 - Two types of cannabinoid receptor have been discovered so far, CB1 (2.1:CBD:1:CB1:), cloned in 1990, and CB2 (2.1:CBD:2:CB2:), cloned in 1993. Distinction between these receptors is based on differences in their predicted amino acid sequence, signaling mechanisms, tissue distribution, and sensitivity to certain potent agonists and antagonists that show marked selectivity for one or the other receptor type. Cannabinoid receptors CB1 and CB2 exhibit 48% amino acid sequence identity. Both receptor types are coupled through G proteins to adenylyl cyclase and mitogen-activated protein kinase. CB1 receptors are also coupled through G proteins to several types of calcium and potassium channels. These receptors exist primarily on central and peripheral neurons, one of their functions being to inhibit neurotransmitter release. Indeed, endogenous CB1 agonists probably serve as retrograde synaptic messengers. CB2 receptors are present mainly on immune cells. Such cells also express CB1 receptors, albeit to a lesser extent, with both receptor types exerting a broad spectrum of immune effects that includes modulation of cytokine release. Of several endogenous agonists for cannabinoid receptors identified thus far, the most notable are arachidonoylethanolamide, 2-arachidonoylglycerol, and 2-arachidonylglyceryl ether. It is unclear whether these eicosanoid molecules are the only, or primary, endogenous agonists. Hence, we consider it premature to rename cannabinoid receptors after an endogenous agonist as is recommended by the International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. Although pharmacological evidence for the existence of additional types of cannabinoid receptor is emerging, other kinds of supporting evidence are still lacking.

AB - Two types of cannabinoid receptor have been discovered so far, CB1 (2.1:CBD:1:CB1:), cloned in 1990, and CB2 (2.1:CBD:2:CB2:), cloned in 1993. Distinction between these receptors is based on differences in their predicted amino acid sequence, signaling mechanisms, tissue distribution, and sensitivity to certain potent agonists and antagonists that show marked selectivity for one or the other receptor type. Cannabinoid receptors CB1 and CB2 exhibit 48% amino acid sequence identity. Both receptor types are coupled through G proteins to adenylyl cyclase and mitogen-activated protein kinase. CB1 receptors are also coupled through G proteins to several types of calcium and potassium channels. These receptors exist primarily on central and peripheral neurons, one of their functions being to inhibit neurotransmitter release. Indeed, endogenous CB1 agonists probably serve as retrograde synaptic messengers. CB2 receptors are present mainly on immune cells. Such cells also express CB1 receptors, albeit to a lesser extent, with both receptor types exerting a broad spectrum of immune effects that includes modulation of cytokine release. Of several endogenous agonists for cannabinoid receptors identified thus far, the most notable are arachidonoylethanolamide, 2-arachidonoylglycerol, and 2-arachidonylglyceryl ether. It is unclear whether these eicosanoid molecules are the only, or primary, endogenous agonists. Hence, we consider it premature to rename cannabinoid receptors after an endogenous agonist as is recommended by the International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. Although pharmacological evidence for the existence of additional types of cannabinoid receptor is emerging, other kinds of supporting evidence are still lacking.

KW - fatty-acid amide

KW - activated protein-kinase

KW - central-nervous-system

KW - hippocampal acetylcholine-release

KW - long-term potentiation

KW - Nigra Pars Reticulata

KW - nitric-oxide release

KW - excitatory synaptic-transmission

KW - mediated signal-transduction

KW - rat cerebellar membranes

U2 - 10.1124/pr.54.2.161

DO - 10.1124/pr.54.2.161

M3 - Literature review

VL - 54

SP - 161

EP - 202

JO - Pharmacological Reviews

JF - Pharmacological Reviews

SN - 0031-6997

IS - 2

ER -